Skip to content

EBITDA at other companies

AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-$34.51M-26.0%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-$116.05M-23.8%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
-$50.68M+11.6%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
-$52.98M-147%
Pfizer logo
PfizerPFE
Amgen logo
AmgenAMGN

Other financials

Income statement

See full
Revenue$2.4M-91.1%
Operating income-$47.1M-84.0%
Net income-$44.2M-95.1%
EPS (diluted)-$0.59-96.7%

Balance sheet

See full
Cash & equivalents$244.3M+221%
Total debt$17.0M-7.7%
Total equity$163.6M-49.7%
Total assets$478.2M+12.4%

Cash flow

See full
Operating cash flow-$45.7M-1,242%
CapEx$216.0K+1,250%
Free cash flow-$45.9M-1,242%

Valuation

See full
Market cap$1.76B+125%
Enterprise value$1.53B+112%
P/S21.6×+13.2×

Profitability

See full
Operating margin-140.4%+7.3pp
Net margin-126.3%+5.0pp
FCF margin-94.8%+15.5pp

Returns & leverage

See full
Return on equity-42%+29.2pp
Debt / equity0.1×0.0×
Current ratio10.8×+6.1×

Where this comes from

Calculated from Zymeworks’s reported figures.

$47.1Mebit+
$1.1MDepreciation Depletion & Amortization
=-$45.98M

The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zymeworks's EBITDA?
Zymeworks (ZYME) reported EBITDA of -$45.98M in Q1 2026.
How has Zymeworks's EBITDA changed year-over-year?
Zymeworks's EBITDA decreased by 99.8% year-over-year, from -$23.02M to -$45.98M.
What is the long-term trend for Zymeworks's EBITDA?
Over 3 years (2022 to 2025), Zymeworks's EBITDA has grown at a -14.9% compound annual growth rate (CAGR), from $137.76M to -$84.82M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.